Family-owned Flamma opens $20m cGMP facility in China
The $20m investment from the contract manufacturing organization (CMO) ups the total capacity of its Chinese operations in Dalian to 200 m3.
Kenneth Drew, Ph.D., sr. director, North America sales and business development told us the main driver to add capacity at its Flamma Honkai facilities in Dalian is to diversify its customer offerings.
“We can now service customers interested in IC4C (In China for China) and we can also sell into the Chinese marketplace with our line of generics like minoxidil and others,” he explained.
Drew said the company has been seeing a growing demand in both in North America and Europe.
“Much of this is thanks to the dedicated staff we have in Italy and in China that help customers achieve their goals,” he added.
Next steps include working towards Chinese FDA inspection.
The company is also looking to add capacity and features to its Italian sites.
The Flamma 2020 plan
According to the company, by 2018 it plans to spend an additional $5m to expand its R&D capabilities with a new facility at its Chignolo d’Isola headquarters.
The goal is to increase production capacity at the facility by 40% with the addition of another cGMP workshop by 2020 – and according to Drew, the “Flamma 2020 plan” is “well on its way to succeed.”
“While the CMO industry appears to be consolidating with mega-mergers and such, we feel that being family owned, privately held and managed company has significant value to customers,” he added.
“We stay true to what we do well and continue to expand our chemical toolbox with new and interesting projects from both old and new customers.”
